Homocysteine: A Cardiovascular and Cognitive Marker

The Biochemistry

Homocysteine is an intermediate in methionine metabolism. It has two fates: remethylation back to methionine, which requires folate and vitamin B12 and the enzyme methionine synthase, and transsulphuration to cysteine, which requires vitamin B6 and the enzyme cystathionine beta-synthase.

When either pathway is limited, homocysteine accumulates. The commonest causes of elevation are low folate, low B12 and low B6 status, impaired kidney function, hypothyroidism, some medications and genetic variants affecting the enzymes.

The methylation connection matters conceptually. Methionine is the precursor of S-adenosylmethionine, the universal methyl donor for DNA methylation, neurotransmitter synthesis and many other reactions, which is why homocysteine is discussed in relation to methylation capacity. That framing is mechanistically real and it does not license the claims often built on it.

The Trial Record

The observational picture was strong. Meta-analyses of prospective studies found elevated homocysteine associated with higher cardiovascular incidence, and Mendelian randomisation using MTHFR variants gave mixed results that some read as supporting causality.

Then the trials ran. Multiple large randomised trials of folic acid with B12 and B6, in patients with vascular disease or at high risk, lowered homocysteine substantially and did not reduce cardiovascular events. Some analyses suggested a small reduction in stroke, which is the one signal that has partly persisted. Cognitive outcome trials have been largely neutral, with possible subgroup effects in people with high baseline homocysteine or low B12 status.

Two readings are possible and both are worth holding. Homocysteine may be a marker of something else, poor nutritional status, impaired kidney function, general ill health, rather than a cause. Or it may be causal over decades in a way that a few years of lowering in people with established disease cannot reverse.

Either way, the practical conclusion is the same: lowering homocysteine for cardiovascular prevention is not supported, and the marker is still worth interpreting for what it indicates.

What It Is Actually Useful For

The B12 use is the strongest case. Serum B12 is an imperfect measure of functional status, and homocysteine alongside methylmalonic acid can detect a functional shortfall in someone whose serum B12 sits within the reference range. That is a genuinely reversible cause of neurological and cognitive symptoms, which makes it worth finding.

Markedly elevated homocysteine, well above the usual range, is a different situation with specific clinical significance including inherited metabolic disorders, and it warrants assessment rather than supplementation.

MTHFR, Handled Honestly

Variants in the MTHFR gene, particularly C677T, reduce the activity of the enzyme converting folate to its active form, and homozygous carriers have modestly higher homocysteine on average.

The variant is common: a substantial proportion of the population carries at least one copy, with frequency varying by ancestry. That commonness is itself informative, since a variant present in a large fraction of healthy people is unlikely to be a major individual determinant of disease.

MTHFR testing has become a fixture of some wellness practices, often with elaborate methylation protocols attached. The evidence does not support that. Major genetics bodies have advised against routine MTHFR testing, on the grounds that it rarely changes management, that the association with outcomes is weak once folate status is accounted for, and that adequate folate intake addresses the functional consequence regardless of genotype.

The practical position: if homocysteine is elevated, address folate, B12 and B6 status and look for kidney and thyroid contributors. Knowing the MTHFR genotype does not change that, and methylated folate forms are a reasonable choice on tolerability grounds without requiring a genetic justification.

Measuring and Interpreting

Reference ranges typically extend to around 15 micromol/L, with many practitioners regarding values below 10 as preferable. Values above 30 are markedly elevated and warrant clinical assessment.

Sample handling matters unusually much. Homocysteine rises in whole blood at room temperature as red cells release it, so delayed separation of plasma falsely raises the result. This is a common source of spurious elevation.

Fasting is generally preferred.

Confounders: impaired kidney function raises it, as do hypothyroidism, some medications including methotrexate, certain anticonvulsants and metformin through B12 effects, smoking, high coffee intake and low physical activity. Age raises it, and it is higher in men.

If elevated: check B12 with methylmalonic acid if available, folate, kidney function and thyroid function. Correct what is low, and re-measure in three months.

Do not: take high-dose B vitamins for cardiovascular prevention on the strength of a homocysteine value, since that is the specific thing the trials tested and did not support.

The Broader Lesson

Homocysteine is worth understanding beyond its own merits, because it is the cleanest available demonstration of a principle that applies across this Journal.

A marker can be reliably associated with an outcome, mechanistically plausible, and responsive to an intervention, and lowering it can still change nothing. The association may reflect an upstream cause affecting both, or the marker may be downstream of the process rather than driving it.

The same reasoning applies to HDL cholesterol, where raising it with niacin did not reduce events, and it is the reason surrogate endpoints require validation rather than assumption. Any recommendation resting on a marker moving, rather than on an outcome changing, inherits this risk.

Applied practically: when a product promises to improve a marker, the question is whether improving that marker by that means has been shown to help. For homocysteine and B vitamins, it has been tested, and the answer is largely no.